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A B S T R A C T 
Sepsis is a common cause of hospital admission 
worldwide and contributes significantly to morbidity 
and mortality. The definition of sepsis has evolved 
from the 1991 American College of Chest Physicians/
Society of Critical Care Medicine definition 
based on the criteria of systemic inflammatory 
response syndrome, to the 2016 Sepsis-3 definition 
that incorporates the Sequential Organ Failure 
Assessment score. The landmark trial on protocolised 
early goal-directed therapy was published in 2001, 
but three subsequent multicentre randomised 
controlled trials (ProCESS, ARISE, and ProMISe) 
in 2014-2015 did not confirm a survival benefit with 
protocolised care. Over the years, there has been 
considerable improvement in sepsis outcome and 
management that hinges on early detection; timely 
source control; prompt, appropriate, and correctly 
Clinical management of sepsis
Introduction
Sepsis is a common cause of hospital admission 
worldwide. The annual incidence of sepsis has 
been reported to be approximately 300 to 1031 per 
100 000 population in the US, and is increasing.1 In-
hospital mortality, however, decreased from 35% in 
2000 to <20% in 2013.2 Numerous studies have been 
performed or are ongoing in this field. The following 
discussion provides an update on the change to 
sepsis definition, three recent trials on protocolised 
early goal-directed therapy (EGDT), and individual 
components of sepsis management.
Defining and recognising sepsis: 
from systemic inflammatory 
response syndrome to Sequential 
Organ Failure Assessment score 
and the role of biomarkers 
In 1991, sepsis was defined as fulfilling two or 
more than two systemic inflammatory response 
syndrome (SIRS) criteria in the presence of infection 
(Table 1).3 Many seriously infected patients (eg old 
or immunocompromised), however, are unable to 
mount a SIRS. Using SIRS criteria to define severe 
sepsis will miss one in eight otherwise similar 
patients with substantial mortality.2 In addition, the 
mortality risk has been shown to increase linearly 
with each additional SIRS criterion and there is no 
transition point noted at a threshold of two SIRS 
criteria.
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 To acknowledge the above shortcomings, the 
Sepsis-3 (Third International Consensus Definitions 
for Sepsis and Septic Shock) in 2016 redefined sepsis 
as “life-threatening organ dysfunction caused by 
a dysregulated host response to infection”.4 Organ 
dysfunction is identified as “an acute change in 
the total Sequential Organ Failure Assessment 
(SOFA) score of ≥2 points” (Table 1). In addition, 
a quick SOFA (qSOFA) score was introduced for 
bedside screening. Meeting two or more than two 
qSOFA criteria (respiratory rate ≥22/min, altered 
mentation with a Glasgow Coma Scale score of <15, 
systolic blood pressure ≤100 mm Hg) should prompt 
consideration of possible infection in undiagnosed 
patients, investigation for organ dysfunction that 
defines sepsis in infected patients, and initiation 
of sepsis management where appropriate.4 Despite 
these recent changes in definition, clinicians should 
maintain a high index of suspicion and always 
consider sepsis as a possible explanation/diagnosis 
when faced with new-onset organ dysfunction in a 
patient. 
 Apart from clinical assessment, various serum 
biomarkers have been studied for their potential 
role in early diagnosis of sepsis. C-reactive protein is 
commonly used but it has a low specificity for sepsis. 
Procalcitonin (PCT) is a prohormone of calcitonin 
that is released into the circulation in response 
to severe systemic inflammation due to bacterial 
infection. A recent meta-analysis showed its clinical 
value in diagnosing sepsis in critically ill patients 
(an area under the receiver operating characteristic 
MEDICAL PRACTICE
dosed antibiotics; aggressive fluid resuscitation; and 
shock reversal. These are all directed by repeated 
bedside assessment. This article summarises recent 
developments and landmark trials that should guide 
current sepsis management.
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膿毒症的臨床治理
林倩雯、劉俊穎、林沛堅、殷榮華
膿毒症（敗血症）是很多國家一個最常見的入院原因，其發病率和死
亡率很高。膿毒症的定義隨着這數十年的演變而有所修正。1991年美
國胸科醫師學院與重症監護醫學學會共同商討，按全身炎症反應綜合
症對膿毒症作定義。直至2016年第三次國際膿毒症共識會上，把器官
衰竭評估分數納入定義中。2001年發表了一項有關早期目標導向的
流程化治療，這項研究極具里程碑意義。可惜2014及2015年進行的
三項多中心隨機對照研究，包括發起於美國的早期膿毒性休克流程化
治療試驗（ProCESS）、發起於澳大利亞和紐西蘭的澳大拉西亞膿毒
症復甦評估試驗（ARISE），以及發起於英國的膿毒症流程化管理試
驗（ProMISe），均未確認流程化治療能提高病人生存效益。這些年
來，膿毒症的治療結果有相當大程度的改善，這取決於早期發現、及
時的病源控制、及時處方適當和正確劑量的抗生素、給予充分性液體
復甦治療，以及休克逆轉。以上各項均透過不斷重複的床邊評估指導
而成。本文總結有關治理膿毒症的最新發展，以及歸納對現行治療方
法相關的具指標性臨床試驗研究。
curve of 0.85).5 The meta-analysis, however, was 
limited by substantial heterogeneity across different 
studies, a wide range of cut-offs used, absence of a 
true reference diagnostic standard, and potential 
publication bias. It is noteworthy that PCT can be 
falsely elevated in inflammation due to other causes, 
such as trauma, rhabdomyolysis, surgery, severe 
pancreatitis, autoimmune disorders, cardiogenic 
shock, and following prolonged resuscitation. It 
cannot be solely relied on to discriminate sepsis from 
other causes of inflammation, but a plasma PCT level 
of ≥0.5 ng/mL is a helpful adjunct when interpreted 
along with additional clinical information and serial 
monitoring might have a role in guiding subsequent 
antibiotic treatment (see below). In case of doubt, 
it is advisable to initiate treatment for sepsis early, 
and adjust subsequent management and antibiotics 
according to the patient’s clinical progress, results of 
investigations, and possibly serial PCT monitoring. 
Update on protocolised 
management: from early goal-
directed therapy to ProCESS-
ARISE-ProMISe 
In 2001, Rivers et al6 randomised 263 patients 
with severe sepsis or septic shock in an emergency 
department (ED) to EGDT or usual care. The 
sequential goals of EGDT were central venous 
pressure (CVP) achieved by fluid resuscitation, 
mean arterial pressure (MAP) with vasopressors, 
and central venous oxygen saturation (ScvO2) with 
red cell transfusion and dobutamine. The result 
was an absolute reduction in in-hospital mortality 
of 16%.6 The protocol was incorporated into the 
surviving sepsis campaign (SSC) 2004, 2008, and the 
2012 Guidelines.7 
 Over the years, concerns have remained 
about the external validity of the original trial, 
TABLE 1.  Old and new definitions of sepsis3
Definitions Comments
Sepsis-1,	1991
Sepsis SIRS*	with	infection	(presumed	or	proven) SIRS	can	be	non-infectious	in	aetiology.	Only	infection	plus	SIRS	
is	termed	sepsis.	Not	all	patients	with	serious	infection	necessarily	
show	SIRS	features	despite	having	organ	dysfunction
Severe	sepsis Sepsis	(as	above)	with	evidence	of	acute	organ	
dysfunction	
Gives	a	false	impression	that	infection	must	go	through	the	three	
stages	of	sepsis,	severe	sepsis,	and	septic	shock;	or	that	organ	
dysfunction	must	have	SIRS
Septic	shock Sepsis	with	persistent	hypotension	after	fluid	
resuscitation
Emphasis	placed	on	circulation	(blood	pressure)	alone	without	
considering	the	metabolic	(lactate)	component
Sepsis-2,	2001 Unchanged	 The	list	of	signs	and	symptoms	associated	with	sepsis	was	expanded
Sepsis-3,	2016
Sepsis Life-threatening	organ	dysfunction†	caused	by	a	
dysregulated	host	response	to	infection
To	recognise	the	finding	that	infections	can	result	in	local	organ	
dysfunction	(reflected	by	the	SOFA	score)	without	triggering	a	
dysregulated	host	response	(the	old	SIRS	criteria)
Septic	shock A	subset	of	sepsis	with	persistent	hypotension	
requiring	vasopressors	to	maintain	MAP	of	 
≥65	mm	Hg	and	a	serum	lactate	level	of	>2	mmol/L	
despite	adequate	volume	resuscitation
The	term	‘severe	sepsis’	is	deleted,	and	both	circulatory	and	
metabolic	abnormalities	are	considered.	Whether	the	new	Sepsis-3	
criteria	improves	clinical	outcomes	remains	to	be	validated
Abbreviations: MAP = mean arterial pressure; SIRS = systemic inflammatory response syndrome; SOFA = Sequential Organ Failure Assessment
* ≥Two of the following: (a) temperature >38°C or <36°C, (b) heart rate >90/min, (3) respiratory rate >20/min or PaCO2 <32 mm Hg (4.3 kPa), (4) 
white blood cell count >12 000/mm3 or <4000/mm3 or >10% immature bands
† Defined by an acute change of ≥2 points in the SOFA score; 6 components including: respiratory (partial pressure of oxygen in arterial blood/fractional 
inspired oxygen [PaO2/FIO2] ratio), neurological (Glasgow Coma Scale score), cardiovascular (MAP and vasopressor use), renal (serum creatinine and 
urine output), hepatic (bilirubin level), and platelet count
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haemodynamic goals, use of CVP and ScvO2 
monitoring, blood transfusion, dobutamine, and 
resultant higher costs of its implementation. 
Subsequently, three large-scale multicentre 
randomised controlled trials were published in 
2014-2015: the ProCESS (Protocolized Care for 
Early Septic Shock) trial,8 the ARISE (Australasian 
Resuscitation in Sepsis Evaluation) trial,9 and the 
ProMISe (Protocolised Management in Sepsis)
trial.10 All three studies were negative; there was no 
survival benefit using protocolised care compared 
with usual care (Table 2).6.8-10 
 A lack of survival benefit of EGDT in the 
latest three trials may be the result of improved 
sepsis management since the original trial: nearly 
all patients received antibiotics within 6 hours of 
presentation, and a significant amount of fluid was 
already administered before randomisation (Table 
2). Treatment in the usual care groups was guided 
by clinical assessment of volume and perfusion 
status, and achieved similar mean and systolic blood 
pressures at the end of the intervention period. 
These trials demonstrated that CVP and ScvO2 goals 
confer no additional benefit for sepsis survival.
 In response to the new evidence, the SSC 
Guidelines updated its 6-hour bundle in April 2015, 
and recommended reassessment in the event of 
persistent arterial hypotension with either physical 
examination or “two of the following (measure CVP, 
measure ScvO2, bedside cardiovascular ultrasound, 
dynamic assessment of fluid responsiveness with 
passive leg raise or fluid challenge)”.11 
TABLE 2.  Comparison of the original EGDT trial, with the ProCESS,  ARISE and ProMISe trials. (a) Study characteristics and (b) interventions and 
outcomes6,8-10
Rivers et al, 20016 ProCESS, 20148 ARISE, 20149 ProMISe, 201510
Country	(No.	of	centres) United	States	(1) United	States	(31) Australia,	New	Zealand,	
Hong	Kong,	Finland,	
Republic	of	Ireland	(51)
England	(56)
Enrolment	period Mar	1997	to	Mar	2000 Mar	2008	to	May	2013 Oct	2008	to	Apr	2014 Feb	2011	to	Jul	2014
No. of patients 263 1341 1600 1260
Usual	care	 133 456 804 630
EGDT 130 439 796 630
Protocol-based	standard	therapy N/A 446 N/A N/A
No.	of	patients	(%	screened)	eligible	but	
not	randomised	due	to	study	logistic	
issues	or	exclusion	by	clinicians	
0 1191	(9.4) 797	(22.4) 1444	(23.3)
(a) Study characteristics
(b) Interventions and outcomes
Abbreviations: APACHE = acute physiology and chronic health evaluation; EGDT = early goal-directed therapy; N/A = not available/applicable
Rivers et al, 20016 ProCESS, 20148 ARISE, 20149 ProMISe, 201510
EGDT Usual 
care
EGDT Protocol-based 
standard 
therapy
Usual 
care
EGDT Usual 
care
EGDT Usual 
care
Baseline	APACHE	II	score 20.4	±	7.4 21.4	±	6.9 20.8	±	8.1 20.6	±	7.4 20.7	±	7.5 15.4	±	6.5 15.8	±	6.5 18.7	±	7.1 18.0	±	7.1
Baseline	lactate	level	(mmol/L) 7.7	±	4.7 6.9	±	4.5 4.8	±	3.1 5.0	±	3.6 4.9	±	3.1 6.7	±	3.3 6.6	±	2.8 7.0	±	3.5 6.8	±	3.2
Total	intravenous	fluid	(mL)
Before	randomisation N/A N/A 2254 2226 2083 2515 2591 2100 2290
0-6	Hours 4981 3499 2805 3285 2279 1964 1713 2000 1784
Antibiotics	within	6	hours	(%) 86.3 92.4 97.5 97.1 96.9 100 100 100 100
Vasopressor	(%) 27.4 30.3 54.9 52.2 44.1 66.6 57.8 53.3 46.6
Dobutamine	(%) 13.7 0.8 8.0 1.1 0.9 15.4 2.6 18.1 3.8
Red	cell	transfusion	(%) 64.1 18.5 14.4 8.3 7.5 13.6 7.0 8.8 3.8
Mechanical	ventilation	(%) 53.0 53.8 26.4 24.7 21.7 22.2 22.4 20.2 19.0
Mortality
In-hospital	(%) 30.5 46.5 N/A N/A N/A 14.5 15.7 25.6 24.6
60-Day	(%)	 44.3 56.9 21.0 18.2 18.9 N/A N/A N/A N/A
90-Day	(%) N/A N/A 31.9 30.8 33.7 18.6 18.8 29.5 29.2
#  Clinical management of sepsis  # 
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Clinical management: initial 
resuscitation and treatment
Source control
Source control includes drainage of any infected 
fluid collection, debridement of infected solid tissue, 
and removal of infected foreign bodies or devices. 
It should best be achieved within 12 hours of 
identification by imaging and/or diagnostic sampling 
of the infection foci. Minimally invasive intervention 
including percutaneous and endoscopic treatments 
should be considered, but surgery is indicated if 
control remains inadequate or if there is diagnostic 
uncertainty. Damage-control surgery for life-
threatening peritonitis is associated with improved 
outcomes.12 It involves an abbreviated initial 
laparotomy for haemorrhage and contamination 
control, followed by resuscitation before the final 
definitive repair and abdominal closure. 
Antibiotics 
Delay in antimicrobial treatment is associated with 
increased mortality, adverse clinical outcome, and 
longer intensive care unit (ICU) and hospital stay.13 
Effective intravenous antimicrobials should be 
initiated as soon as possible after recognition and 
within 1 hour for both sepsis and septic shock.14 
One study showed that each hour delay reduces 
survival by 7.6% in the first 6 hours following the 
onset of septic shock.15 Although a recent meta-
analysis pooling data from 11 observational studies 
showed no survival benefit of early antibiotic 
therapy,16 it failed to analyse all eligible studies 
and lacked microbiological considerations. Early 
therapy remains logical, especially in patients with 
severe infections, although the optimum time frame 
for administration remains unknown.17 Delay in 
administration can occur anywhere, from ED triage, 
making a diagnosis, antibiotic order, drug dispensary 
to the actual administration, and should be addressed 
with clinical, administrative, and logistics measures 
to improve timeliness of treatment. 
 The choice of initial empirical antimicrobials 
should be broad enough to cover the likely pathogens, 
while also taking into account recent culture results, 
host factors, and susceptibility patterns. The EPIC 
II (Extended Prevalence of Infection in Intensive 
Care) study showed that in Asia, the common 
infective sources are the respiratory system, 
abdomen, blood stream, and renal/urinary tract, 
while the commonest organisms are Streptococcus 
pneumoniae, vancomycin-sensitive Enterococcus, 
Klebsiella spp, Pseudomonas spp, and Acinetobacter 
spp.18 Local microbiologists can regularly provide 
antibiotic sensitivity patterns for reference. 
 Combination therapy, defined as administration 
of two or more different classes of antimicrobials with 
different mechanisms of action, has the advantages 
of broadening the spectrum of coverage, and possible 
additive or synergistic effects on pathogens. Meta-
analyses showed that combination antibiotic therapy 
improves survival in the most severely ill patients 
with septic shock, but may be detrimental to low-
risk patients and increases nephrotoxicity.19,20 Once 
the causative pathogens and their susceptibility 
patterns are known, de-escalation of antimicrobial 
therapy should follow to prevent development of 
resistance, as well as reduce drug toxicity and cost. 
Discontinuing antibiotics can be considered when 
PCT is ≤0.5 ng/mL or serial monitoring shows a 
decline of ≥80% of its peak value.21
 Appropriate antibiotic dosing to achieve 
effective bacterial killing while preventing toxicity 
and emergence of resistance is also important. This 
is particularly relevant in critically ill patients with 
substantial pharmacokinetic variability (Table 3), 
who are infected by pathogens with higher minimum 
inhibitory concentrations (MIC). Individualised 
dosing adjustment requires knowledge of 
pharmacokinetic targets and MIC for the organism. 
Readers can refer to published reviews for specific 
recommendations.22,23 In general, changes to the 
volume of distribution will affect initial dosing, while 
changes in drug clearance will affect the maintenance 
dose. Killing by time-dependent antibiotics (eg β-
lactams) correlates with the time fraction when 
serum drug concentration exceeds MIC. This can be 
achieved by frequent dosing and use of continuous 
infusion. Conversely, concentration-dependent 
killing (eg aminoglycosides) correlates with the ratio 
of peak drug concentration to MIC. A higher dosage 
with extended dosing intervals will maximise killing 
while minimising toxicity. Due to the complexity and 
variability of various factors at play, therapeutic drug 
monitoring has been advocated in the critically ill 
patients but remains to be available universally.22-24 
Therapeutic drug monitoring involves direct 
measurement of serum antibiotic concentrations 
and timely comparison with a therapeutic target to 
facilitate adjustments by the clinician or any dosing 
software. 
Fluid
Type of fluid 
Choice of non-blood product can be broadly divided 
into crystalloids and colloids. Crystalloids include 
normal saline or balanced solutions (eg lactated 
Ringer’s solution [B Braun, US], Hartmann’s solution 
[Fresenius Kabi, Australia], Plasma-Lyte 148 [Baxter, 
US]). Colloids include natural human albumin and 
semi-synthetic solutions (gelatin-like Gelofusine [B 
Braun, US] or Haemaccel [Sanofi, France], dextran, 
and hydroxyethyl starch). Normal saline has a high 
chloride content and may produce hyperchloraemic 
acidosis and renal vasoconstriction. Balanced 
solutions minimise these side-effects by using lactate 
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or acetate as buffers. Weak evidence suggests that 
balanced solutions compared with normal saline 
reduce acute kidney injury (AKI), the need for 
renal replacement therapy (RRT), and mortality in 
sepsis.25,26 Nonetheless, the recent SPLIT trial did 
not find a difference in AKI among a heterogeneous 
group of ICU patients who received a balanced 
crystalloid or saline, although the study recruited 
predominantly postoperative patients at low risk 
who received small doses (median, 2 L) of fluid.27 
 Colloids theoretically maintain a higher 
oncotic pressure and hence intravascular volume 
but the CRISTAL (Colloids Versus Crystalloids for 
the Resuscitation of the Critically Ill) trial found 
no mortality difference among ICU patients with 
hypovolaemic shock who were resuscitated with 
either colloids or crystalloids.28 Dextran has ceased to 
be a resuscitation fluid due to its high anaphylactoid 
potential, impact on platelet aggregation with 
resultant bleeding complications, and interference 
with erythrocyte cross-matching. Gelatins have the 
highest risk among the colloids for anaphylactoid 
reaction and the lowest intravascular persistence 
due to their rapid urinary excretion. Hydroxyethyl 
starch is not advisable for acute volume resuscitation 
because it deposits in the kidneys, liver, skin and other 
tissues, and is associated with increased mortality, 
AKI, new-onset hepatic failure, and higher incidences 
of pruritus and rash.29-32 Concerning albumin, the 
SAFE (Saline versus Albumin Fluid Evaluation) 
trial33 demonstrated no survival benefit among a 
general ICU population when either 4% albumin 
or normal saline was used for fluid resuscitation, 
but predefined subgroup analysis suggested a trend 
towards improved survival in patients with severe 
sepsis who received albumin solution. A decade later, 
however, the ALBIOS (Albumin Italian Outcome 
Sepsis) study of patients with severe sepsis could not 
confirm a survival benefit when albumin was used in 
addition to crystalloids compared with crystalloids 
alone to maintain a serum albumin level of ≥30 g/L, 
although there was a small haemodynamic 
advantage and post-hoc subgroup analysis showed a 
significantly lower 90-day mortality in patients with 
septic shock who received albumin.34 
 In summary, crystalloids (possibly balanced 
solutions) remain the initial fluid of choice in the 
resuscitation of sepsis. Routine use of albumin is 
not warranted given its higher cost, but it may be 
considered in patients with septic shock who do 
not respond to crystalloid. There is no evidence 
that gelatins are more beneficial, and dextran and 
hydroxyethyl starch should be avoided. 
Assessment of fluid responsiveness
Both under- and over-hydration can be harmful.35 It 
is therefore recommended that 30 mL/kg crystalloid 
be given with reassessment of fluid responsiveness 
(defined as >10%-15% increase in stroke volume 
in response to volume administration) or tissue 
perfusion afterwards. Static indices like CVP 
and pulmonary capillary wedge pressure are not 
good indicators of fluid responsiveness, and are 
not recommended for use to guide fluid therapy. 
Dynamic indices obtained by inducing a change 
in the preload and monitoring the corresponding 
change in cardiac output (CO) or its derivatives 
should be used instead (Table 4). 
 An arterial waveform pulse pressure variation 
(PPV) of >13%, induced by heart-lung interactions 
TABLE 3.  Factors affecting antibiotic pharmacokinetics in critically ill patients
Factor Cause/definition Implication
Fluid	overload Capillary	leakage	and	fluid	
extravasation	from	SIRS,	compounded	
by	fluid	resuscitation
Increases	volume	of	distribution	for	hydrophilic	antibiotics	(eg	β-lactams,	
aminoglycosides,	vancomycin,	and	linezolid).	Reduces	the	time	to	reach	
effective	therapeutic	concentration
Hypoalbuminaemia	 Serum	albumin	<25	g/L Raises	unbound	fraction	of	protein-bound	antibiotics	(eg	ceftriaxone,	
flucloxacillin,	ertapenem,	and	daptomycin)	resulting	in:
1.	 raised	antibiotic	activity	(unbound	fraction)	in	the	early	dosing	interval
2.	 increased	volume	of	distribution	reduces	peak	concentration
3.	 increased	elimination	in	the	later	dosing	interval
Microvascular	failure Sepsis	and	use	of	vasopressors Impairs	tissue	penetration	of	antibiotics.	Serum	concentration	becomes	an	
imprecise	guide
Augmented	renal	
clearance
Vasodilation,	increased	cardiac	output,	
and	enhanced	renal	perfusion
Increases	elimination	of	antibiotics	predominantly	excreted	by	the	kidneys	(eg	
β-lactams,	aminoglycosides,	vancomycin)
Acute	kidney	injury Multi-organ	dysfunction	syndrome Impairs	elimination	of	antibiotics	predominantly	excreted	by	the	kidneys	(eg	
β-lactams,	aminoglycosides,	vancomycin).	The	effect	of	RRT	on	antibiotic	
dosing	is	dependent	on	the	mode	and	dose	of	RRT,	and	the	sieving	or	
saturation	coefficient	of	the	antibiotic
Hepatic	dysfunction Multi-organ	dysfunction	syndrome Impairs	elimination	of	antibiotics	predominantly	cleared/metabolised	by	the	liver	
(eg	tigecycline)
Abbreviations: RRT = renal replacement therapy; SIRS = systemic inflammatory response syndrome
#  Clinical management of sepsis  # 
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during mechanical ventilation, predicts fluid 
responsiveness with a high degree of accuracy in 
controlled settings.36,37 Its accuracy, however, is 
lowered by arrhythmia, spontaneous breathing 
activity, low-tidal-volume ventilation (<8 mL/kg 
ideal body weight), low heart-rate-to-respiratory-
rate ratio (<3.6), and right ventricular dysfunction 
(peak systolic velocity of tricuspid annulus <0.15 
m/s). Raised intra-abdominal pressure (IAP) 
exaggerates PPV, and one study found that PPV/
IAP of <1.41 could identify false-positive patients.38 
These confounders limit the application of PPV 
in routine clinical practice, in particular during 
protective ventilation for acute respiratory distress 
syndrome (ARDS). 
 A virtual fluid challenge test with passive leg 
raising can avoid the above caveats as it does not 
rely on mechanical ventilation to induce changes 
in preload and, unlike other methods, has been 
validated in patients with breathing efforts and 
arrhythmia. When coupled with CO monitoring, 
passive leg raising has an excellent predictive 
accuracy.39 Accuracy drops when arterial pulse 
pressure instead of CO is used, as well as in patients 
with raised IAP of ≥16 mm Hg.40
 A mini-fluid challenge (100 mL infused rapidly 
over 1 minute) is an alternative method and limits 
cumulative positive fluid balance in non-responders. 
Unlike PPV, it remains accurate at times of low-
tidal-volume ventilation.41 
 Respiratory variation of the inferior vena 
cava diameter is another accurate marker of fluid 
responsiveness in patients who are mechanically 
ventilated,42 but its use in spontaneously breathing 
patients is more controversial. 
Vasopressors
Guidelines of SSC recommend maintaining MAP at 
a minimal of 65 mm Hg.14 The SEPSISPAM (Sepsis 
and Mean Arterial Pressure) Investigators studied 
776 septic shock patients, and found that targeting 
a MAP of 80-85 mm Hg rather than 65-70 mm Hg 
did not result in any difference in 28- or 90-day 
mortality.43 A vasopressor should be considered 
when MAP of ≥65 mm Hg cannot be maintained 
despite adequate fluid resuscitation. 
 For the choice of vasopressors, studies 
that compared norepinephrine (with or without 
additional dobutamine in patients with low CO) 
with epinephrine found no difference in all-cause 
28-day mortality,44 or the time to achievement of a 
clinician-prescribed MAP goal.45 Epinephrine use 
was associated with significant tachycardia and 
lactic acidosis that did not affect haemodynamic 
stabilisation or survival. The hyperlactataemia 
represents exaggerated aerobic glycolysis instead 
TABLE 4.  Assessment of fluid responsiveness
Technique Setting Device Threshold values for fluid 
responsiveness
PPV Mechanically	ventilated	with	tidal	
volume	≥8	mL/kg,	in	the	absence	of	
spontaneous	breathing	activity	and	
arrhythmias
Arterial	blood	pressure	transducer	 
and	patient	monitor
100	x	(Ppmax	-	Ppmin)/[(Ppmax	+	
Ppmin)/2]	≥13%
Passive	leg	raising	 Validated	in	the	presence	of	
spontaneous	breathing	and	arrhythmias
Device	to	measure	cardiac	
output	or	surrogate	(transthoracic	
echocardiography,	oesophageal/
transthoracic	Doppler,	calibrated	
pulse	contour	analysis,	bioreactance,	
pulmonary	artery	catheter,	arterial	
blood	pressure	transducer)
Depending	on	index	used	 
Aortic	or	subaortic	VTI	increases	≥15%;	
accuracy	drops	if	assessed	by	changes	
in	pulse	pressure	instead	of	cardiac	
output	or	surrogate
Mini-fluid	challenge Mechanically	ventilated	at	low-tidal-
volume	(<8	mL/kg	ideal	body	weight)	
patients	without	spontaneous	breathing	
or	arrhythmias	challenged	with	100	mL	
4%	human	albumin	over	1	min
Arterial	blood	pressure	transducer	 
and	patient	monitor
ΔPPV100 ≥2%
Respiratory	variation	
of	inferior	vena	cava
Mechanically	ventilated	with	tidal	
volume	≥8	mL/kg
Echocardiography	 100	x	(Dmax	-	Dmin)/Dmin	≥18%
100	x	(Dmax	-	Dmin)/[(Dmax	+	Dmin)/2]	
≥12%
Spontaneously	breathing	 Echocardiography 100	x	(Dmax	-	Dmin)/Dmax	≥40%	
AUC	of	ROC	=	0.77	only:	a	value	≥40%	
more	likely	to	be	fluid	responsive,	
but	<40%	cannot	exclude	fluid	
responsiveness
Abbreviations: AUC = area under curve; Dmax / Dmin = maximum / minimum IVC diameter; IVC = inferior vena cava; Ppmax / Ppmin = maximal / minimal 
pulse pressure; PPV = pulse pressure variation; ΔPPV
100
 = reduction in pulse pressure variation after 100-mL mini-fluid challenge; ROC = receiver operating 
characteristic curve; VTI = subaortic velocity time index
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of ongoing tissue hypoxia, but potentially interferes 
with interpretation of serial serum lactate 
measurements. The 2008 VASST (Vasopressin and 
Septic Shock Trial)46 randomised 779 septic shock 
patients to receive either norepinephrine alone or 
norepinephrine plus low-dose vasopressin (0.03 
U/min), and found no difference in all-cause 28-day 
mortality. The SOAP II Trial randomised 1679 
patients with shock to receive either norepinephrine 
or dopamine, and found no difference in all-cause 
28-day mortality but a significantly higher rate of 
arrhythmias in the dopamine group (the number 
needed to harm was 9). In their subgroup analysis, 
dopamine was associated with higher mortality in 
cardiogenic shock, but not septic and hypovolaemic 
shock.47 
 Norepinephrine is therefore recommended 
as the first-line vasopressor for septic shock. 
In refractory hypotension, epinephrine or low-
dose vasopressin (0.03 units/min) may be added. 
Dopamine should be avoided except in highly 
selected patients who are bradycardic and at low risk 
of tachyarrhythmias.
Resuscitation endpoints
The optimal goal for sepsis resuscitation remains 
unknown. While under resuscitation is detrimental, 
achieving supranormal targets has also been shown 
to cause harm.48 The MAP (perfusion pressure) 
of ≥65 mm Hg and urine output of ≥0.5 mL/kg/h 
are the recommended targets. The EMShockNet 
Trial showed that there was no difference in 
hospital mortality when using lactate clearance 
(>10%) or ScvO2 (>70%) as goals of early sepsis 
resuscitation.49 Hyperlactataemia in sepsis, however, 
can result from increased production driven by 
endogenous or exogenous epinephrine-stimulated 
aerobic glycolysis, endotoxin inhibition of pyruvate 
dehydrogenase, and decreased lactate metabolism 
due to liver and renal dysfunction. Thus, persistent 
hyperlactataemia does not necessarily indicate 
anaerobic metabolism and tissue hypoxia, and should 
not be solely relied on to guide therapy that aims to 
boost oxygen delivery in patients who are otherwise 
clinically improving. Conversely, normalisation of 
serum lactate is reassuring as it is associated with 
reduced hospital mortality in critically ill patients.50 
Adjunctive therapy
Blood transfusion
In the original EGDT protocols, once ScvO2 
drops below 70%, blood transfusion to achieve a 
haematocrit level of ≥30% was recommended to 
boost oxygen delivery. The 1999 TRICC (Transfusion 
Requirements in Critical Care) trial demonstrated 
lower rates of in-hospital mortality with a restrictive 
rather than liberal transfusion strategy. This trial, 
however, excluded septic shock patients. The 2014 
TRISS (Transfusion Requirements in Septic Shock) 
trial randomised 998 septic shock patients to either a 
liberal blood transfusion strategy with a transfusion 
threshold of haemoglobin of ≤90 g/L or a restrictive 
strategy with a threshold of ≤70 g/L.51 Mortality at 90 
days, rate of ischaemic events, and use of life support 
were similar. A transfusion threshold of 70 g/L is 
therefore recommended. For patients with ongoing 
acute coronary syndrome or chronic cardiovascular 
disease, targeting a higher haemoglobin level of 100 g/L 
might be beneficial but remains to be proven.52 
Glucocorticoids
Glucocorticoids have anti-inflammatory and 
immunosuppressive effects. Despite the positive 
Annane Trial in 2002, the subsequently larger 
multicentre CORTICUS (Corticosteroid Therapy of 
Septic Shock) Trial53 was negative. It randomised 499 
patients with septic shock to receive 6-hourly 50-mg 
hydrocortisone or placebo, with the dose tapered 
over 11 days. Hydrocortisone did not improve 28-day 
survival in patients with septic shock, and should not 
be routinely used for septic shock before adequate 
fluid resuscitation and vasopressor therapy.14 If used 
in refractory shock, early administration within 9 
hours of commencement of vasopressor is advised.54 
Glucose control
Tight glycaemic control (blood glucose, 4.4-6.1 mmol/L) 
was once commonly practised after the 2001 
Leuven Surgical Trial. In 2009, the NICE-SUGAR 
(Normoglycemia in Intensive Care Evaluation—
Surviving Using Glucose Algorithm Regulation) 
study randomised 6104 ICU patients, and showed 
that intensive glucose control (4.5-6.0 mmol/L) 
increased mortality compared with a target of <10 
mmol/L.55 Post-hoc analysis further demonstrated 
an association between hypoglycaemia and 
an increased risk of death in a dose-response 
relationship. This association was strongest for 
death from distributive, including septic shock.56 
Guidelines of SSC recommend targeting an upper 
blood glucose level of <10 mmol/L to reduce the risk 
of hypoglycaemia.14
Organ support
Kidney
The optimal timing of RRT in the absence of overt 
life-threatening complications (severe metabolic 
acidosis, hyperkalaemia, and/or fluid overload) is 
uncertain. Prior studies as well as the recent ELAIN 
(Early vs Late Initiation of Renal Replacement 
Therapy in Critically Ill Patients With Acute Kidney 
Injury57) and AKIKI (Artificial Kidney Initiation in 
Kidney Injury58) trials have yielded contradictory 
results, partly because of the heterogeneous 
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definitions of ‘early’ and ‘late’ initiation of RRT. It 
is hoped that the upcoming IDEAL-ICU (Initiation 
of Dialysis Early versus Delayed in Intensive 
Care Unit59) and STARRT-AKI (Standard versus 
accelerated initiation of renal replacement therapy 
in acute kidney injury60) trials will provide more 
evidence on the subject. Regarding the intensity of 
renal support in critically ill patients with AKI, an 
effluent rate of 25 mL/kg/h is considered adequate 
and high-volume haemofiltration is not superior.61,62 
Survival benefit of blood purification strategies has 
yet to be proven. 
Lungs
Of note, ARDS is a frequent complication of sepsis. 
Optimal ventilatory support prevents further lung 
injury and the resultant biotrauma from cytokine 
release. A lung protective strategy with low tidal 
volume (6 mL/kg ideal body weight) remains the 
cornerstone of treatment.63 A higher positive end-
expiratory pressure should be reserved for patients 
with moderate-to-severe ARDS as defined by the 
latest Berlin definition.64 Early (intubated for <36 
hours) and sustained (≥16 consecutive hours per 
day) prone positioning in moderate-to-severe ARDS 
has proven survival advantage when practised in 
conjunction with lung protective ventilation.65 
Conclusion 
Optimal sepsis management involves both refinement 
of clinical interventions and administrative logistics 
for the timeliness of their delivery. Early recognition 
of sepsis, timely source control, prompt and effective 
antibiotic administration at the right dose, immediate 
fluid resuscitation as guided by bedside reassessment, 
and dynamic indices of fluid responsiveness remain 
the mainstay of sepsis management.
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